Figure 2
Maturation of dendritic cells (DCs) from healthy donors or from breast cancer patients. Data are expressed as the percentage of the cells (with standard error) expressing the CD80, CD83 and CD86 surface markers after treatment of immature DCs with a combination of maturating agents: (a) tumour necrosis factor (TNF)-α/lipopolysaccharide (LPS)/CD40L (n = 3); (b) IL-1β/IL-6/TNF-α/prostaglandin (PG)E2 (n = 4–5); and (c) Ribomunyl®/Imukin® (n = 3). aDifferent from corresponding donors in each individual assay.
